General Medicine: Open Access

ISSN - 2327-5146

Mora F

Mora F


  • Research Article
    Use of Rapamycin in Pediatric Patients with Autosomal Dominant Polycystic Kidney Disease
    Author(s): Liern JM, Codianni P, Mora F, Blumenthal L and Vallejo GLiern JM, Codianni P, Mora F, Blumenthal L and Vallejo G

    Background: Autosomal dominant polycystic disease (ADPKD) is characterized by the development of renal cysts. Objectives: 1) To assess the kidney and cyst volume growth in patients treated with Rapamycin compared to patients who receive standard ADPKD treatment. 2) Evaluate the occurrence of adverse effects related to the use of Rapamycin. 3) To assess the changes in blood pressure, proteinuria and estimated Glomerular Filtration rate (eGFR). Materials and Methods: During 24 months were randomized 12 patients with ADPKD in a Rapamycin group (6 patients, received rapamycin 2-3 mg/m2/day, max. 5mg/día) and a Control group (standard treatment). Results: Of the 12 patients, 6 entered the Rapamycin group and had a total renal volume and cystic volume increase at study completion of 13% and 32% respectively. In the Control group (6 patients) the increases were 11% and 23% respectively. The eGF.. Read More»
    DOI: 10.4172/2327-5146.1000160

    Abstract PDF

Relevant Topics